Bioservo Technologies AB Interim Report January – March 2023
First quarter in figures · Net sales of SEK 4.6 M (2.9) · EBITDA of SEK -8.9 M (-11.0) · EBIT of SEK -9.4 M (-12.1) · Earnings for the period amounted to SEK -9.4 M (-12.1) · Earnings per share before and after dilution amounted to SEK -0.49 (-0.64) · Cash flow from operating activities for the period amounted to SEK -12.8 M (-12.4) Significant events during the period · In January 2023, the new Carbonhand was delivered to the first patients in Sweden, Norway, and Germany. The order backlog at year-end 2022 amounted to approximately 40 units. · Waupaca Foundry,